BioCentury | Apr 15, 2013
Clinical News

NeXstar preclinical data

...to stop influx of neutrophils and reduce lung injury in a rat model of ARDS. NeXstar Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

Sequus preclinical data

...more effective than amphotericin B or The Liposome Co Inc.'s Abelcet , and equivalent to NeXstar Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Company News

The Liposome, NeXstar enabling technology, drug delivery news

...NXTR originally filed the suit in May 1993. The Liposome Co. Inc. (LIPO), Princeton, N.J. NeXstar Pharmaceuticals Inc....
BioCentury | May 3, 2012
Tools & Techniques

Evolution not revolution

...in 1991 to commercialize the procedure. In 1995, NeXagen and Vestar Inc. merged to become NeXstar...
BioCentury | Feb 28, 2011
Strategy

Gilead's cancer encore

...Inc. last June. Gilead's first foray into cancer drug development was its 1999 acquisition of NeXstar Pharmaceuticals Inc....
BioCentury | Jan 7, 2010
Tools & Techniques

Going live with aptamers

...Inc. in 1991 to commercialize SELEX. In 1995 NeXagen and Vestar Inc. merged to become NeXstar...
BioCentury | Aug 3, 2009
Strategy

Questions of the heart

...it needs to expand into new therapeutic areas since 1999. At that time, it bought NexStar Pharmaceuticals Inc....
BioCentury | Feb 19, 2009
Tools & Techniques

Apt screening with microfluidics

...in 1991 to commercialize the technology. In 1995 NeXagen and Vestar Inc. merged to become NeXstar...
BioCentury | Mar 24, 2008
Finance

Ebb & Flow Focus

...the regulatory strategy and building a commercial infrastructure. The CEO, Pat Mahaffy, had been at NeXstar...
...building a commercial team," said Pollard-Knight. "We saw it as a very late-stage product play." NexStar Pharmaceuticals Inc....
BioCentury | Jan 22, 2007
Strategy

Aptamer family tree

...the 1990s, Gold founded NeXagen, which became NeXstar following a merger with Vestar. In 1999, NeXstar...
Items per page:
1 - 10 of 224
BioCentury | Apr 15, 2013
Clinical News

NeXstar preclinical data

...to stop influx of neutrophils and reduce lung injury in a rat model of ARDS. NeXstar Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Clinical News

Sequus preclinical data

...more effective than amphotericin B or The Liposome Co Inc.'s Abelcet , and equivalent to NeXstar Pharmaceuticals Inc....
BioCentury | Apr 15, 2013
Company News

The Liposome, NeXstar enabling technology, drug delivery news

...NXTR originally filed the suit in May 1993. The Liposome Co. Inc. (LIPO), Princeton, N.J. NeXstar Pharmaceuticals Inc....
BioCentury | May 3, 2012
Tools & Techniques

Evolution not revolution

...in 1991 to commercialize the procedure. In 1995, NeXagen and Vestar Inc. merged to become NeXstar...
BioCentury | Feb 28, 2011
Strategy

Gilead's cancer encore

...Inc. last June. Gilead's first foray into cancer drug development was its 1999 acquisition of NeXstar Pharmaceuticals Inc....
BioCentury | Jan 7, 2010
Tools & Techniques

Going live with aptamers

...Inc. in 1991 to commercialize SELEX. In 1995 NeXagen and Vestar Inc. merged to become NeXstar...
BioCentury | Aug 3, 2009
Strategy

Questions of the heart

...it needs to expand into new therapeutic areas since 1999. At that time, it bought NexStar Pharmaceuticals Inc....
BioCentury | Feb 19, 2009
Tools & Techniques

Apt screening with microfluidics

...in 1991 to commercialize the technology. In 1995 NeXagen and Vestar Inc. merged to become NeXstar...
BioCentury | Mar 24, 2008
Finance

Ebb & Flow Focus

...the regulatory strategy and building a commercial infrastructure. The CEO, Pat Mahaffy, had been at NeXstar...
...building a commercial team," said Pollard-Knight. "We saw it as a very late-stage product play." NexStar Pharmaceuticals Inc....
BioCentury | Jan 22, 2007
Strategy

Aptamer family tree

...the 1990s, Gold founded NeXagen, which became NeXstar following a merger with Vestar. In 1999, NeXstar...
Items per page:
1 - 10 of 224